TORONTO, March 13, 2017 /PRNewswire/ - Merus Labs International Inc. ("Merus" or the "Company") [TSX: MSL,NASDAQ: MSLI] announces that the board of directors of the Company has approved minor amendments to its stock option plan (the "Plan"). The amendments have been proposed to address issues raised by Institutional Shareholder Services ("ISS")
The amendments to the Plan to address the ISS recommendations will:
The amendments to the Plan to address the TSX administrative changes will:
The amendments to the Plan are not expected to substantively impact on the Company's compensation practices moving forward. Merus has made the amendments in recognition that such changes bring the Plan into closer alignment with the latest corporate governance best practices for a company of the size and development of Merus.
The amendments to the Plan have been approved by the Board and will be put forward to shareholders for their approval at the AGM. Shareholders may view a copy of the proposed updated Plan at the Company's website at "www.meruslabs.com" on the "Investors" page under "Annual Meeting".
About Merus Labs
Merus Labs is a specialty pharmaceutical company focused on acquiring and optimizing established and growth products. The Company leverages its expertise and commercial platform in Europe, Canada and select other markets to deliver value.
Certain statements contained in this press release may constitute "forward-looking statements" within the meaning of the United States Private Securities Litigation Reform Act of 1995 and applicable Canadian securities legislation. Forward-looking statements include statements relating to approval of the Plan at the AGM, the Company's future business and operating plans, including potential changes to capital structure, product acquisitions or prospective corporate transactions. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the Company's actual results to be materially different from any future results expressed or implied by these statements. Such factors include the following: general economic and business conditions, changes in demand for Merus' products, changes in competition, the ability of Merus to integrate acquisitions or complete future acquisitions, Merus' ability to complete any financing, interest rate fluctuations, currency exchange rate fluctuations, dependence upon and availability of qualified personnel and changes in government regulation. Investors should refer to the Company's MD&A, Annual Information Form and Annual Report on 40-F for the year ended September 30, 2016 for a more comprehensive discussion of the risks that are material to the Company and its business. These forward-looking statements speak only as of the date of this press release, and Merus undertakes no obligation to update or revise the statements.
SOURCE Merus Labs Inc.
Subscribe to our Free Newsletters!
A patient's struggle with Issacs' syndrome with no cure. Also known as neuromyotonia it is a rare ...
Inguinal hernia surgery is a procedure to repair a weak spot or defect in the lower wall of the ...
Hypopituitarism is a rare disorder resulting from decreased secretion of one or more of the ...View All